Reappraisal of Quantitative Gel Zymography for Matrix Metalloproteinases

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2014 Mar 21

PMID 24648291

Citations 4

Authors

Tommaso Prescimone

Danika Tognotti

Chiara Caselli

Manuela Cabiati

Andrea DAmico

Silvia Del Ry

Daniela Giannessi

Affiliations

Soon will be listed here.

Abstract

Background: The determination of matrix metalloproteases (MMPs) is relevant in many pathophysiological conditions, especially if associated with extracellular matrix remodeling; however, the results obtained are closely linked to the method used and are not directly comparable. The aim of this study was to perform a reappraisal of quantitative gel zymography technique for MMPs in human plasma, to use for comparison with commercially available ELISA and in those experimental conditions where the MMP active form needs to be revealed.

Methods: The critical methodological parameters of zymography were checked and a comparison with a routinely used ELISA was performed.

Results: Sensitivity and reproducibility levels of zymography are suitable for detection of MMP-9 in human plasma, providing results closely related to those obtained by ELISA.

Conclusions: Analytical parameters of zymography were suitable for detection of MMPs in human plasma. Quantitative zymography for MMPs is an alternative method for comparing the results of ELISA widely employed for MMP determination, thus reducing the discrepancies between laboratories regarding gelatinase assay.

Citing Articles

Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome.

Laroui A, Galarneau L, Abolghasemi A, Benachenhou S, Plantefeve R, Bouchouirab F Sci Rep. 2022; 12(1):15386.

PMID: 36100610 PMC: 9470743. DOI: 10.1038/s41598-022-19476-y.

Antiphotoaging properties of essential oil isolated by solvent-free microwave extraction against ultraviolet B-irradiated human dermal fibroblasts.

Navabhatra A, Maniratanachote R, Yingngam B Toxicol Res. 2022; 38(2):235-248.

PMID: 35419276 PMC: 8960501. DOI: 10.1007/s43188-021-00107-z.

In Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach.

Tabernilla A, Dos Santos Rodrigues B, Pieters A, Caufriez A, Leroy K, Van Campenhout R Int J Mol Sci. 2021; 22(9).

PMID: 34068678 PMC: 8126138. DOI: 10.3390/ijms22095038.

Change in Proteolytic Profile in Heifers After Oligofructose Overload.

Li S, Zheng X, Ding M, Tao Z, Zhang J, Zhang N Front Vet Sci. 2021; 7:580375.

PMID: 33392282 PMC: 7775515. DOI: 10.3389/fvets.2020.580375.

References

Ranuncolo S, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L . Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer. 2003; 106(5):745-51. DOI: 10.1002/ijc.11288. View

Blankenberg S, Rupprecht H, Poirier O, Bickel C, Smieja M, Hafner G . Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107(12):1579-85. DOI: 10.1161/01.CIR.0000058700.41738.12. View

Tanaka K, Essick E, Doros G, Tanriverdi K, Connors L, Seldin D . Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc. 2013; 2(2):e005868. PMC: 3647258. DOI: 10.1161/JAHA.112.005868. View

Uzuelli J, Dias-Junior C, Tanus-Santos J . Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta. 2007; 388(1-2):184-8. DOI: 10.1016/j.cca.2007.11.001. View

Souza-Tarla C, Uzuelli J, Machado A, Gerlach R, Tanus-Santos J . Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem. 2005; 38(5):410-4. DOI: 10.1016/j.clinbiochem.2005.02.010. View

Snoek-van Beurden P, Von den Hoff J . Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005; 38(1):73-83. DOI: 10.2144/05381RV01. View

Rizzi E, Castro M, Prado C, Silva C, Fazan Jr R, Rossi M . Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail. 2010; 16(7):599-608. DOI: 10.1016/j.cardfail.2010.02.005. View

Kleiner D, Stetler-Stevenson W . Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994; 218(2):325-9. DOI: 10.1006/abio.1994.1186. View

Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D . Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem. 1998; 44(5):1060-2. View

10.

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

11.

Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M . Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer. 2000; 89(4):389-94. DOI: 10.1002/1097-0215(20000720)89:4<389::aid-ijc12>3.0.co;2-j. View

12.

Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg J . Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2010; 278(1):28-45. DOI: 10.1111/j.1742-4658.2010.07920.x. View

13.

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

14.

Neto-Neves E, Dias-Junior C, Rizzi E, Castro M, Sonego F, Gerlach R . Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med. 2010; 39(2):349-56. DOI: 10.1097/CCM.0b013e3181fa3dfe. View

15.

Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D . Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem. 1997; 30(6):491-6. DOI: 10.1016/s0009-9120(97)00097-0. View

16.

Neto-Neves E, Kiss T, Muhl D, Tanus-Santos J . Matrix metalloproteinases as drug targets in acute pulmonary embolism. Curr Drug Targets. 2013; 14(3):344-52. DOI: 10.2174/1389450111314030006. View

17.

Castro M, Kandasamy A, Youssef N, Schulz R . Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res. 2011; 64(6):551-60. DOI: 10.1016/j.phrs.2011.05.005. View

18.

Overall C . Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol. 2002; 22(1):51-86. DOI: 10.1385/MB:22:1:051. View

19.

Brew K, Dinakarpandian D, Nagase H . Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1-2):267-83. DOI: 10.1016/s0167-4838(99)00279-4. View

20.

Abaci O, Kocas C, Orta Kilickesmez K, Uner S, Kucukoglu S . Matrix metalloproteinase-2 and -9 levels in patients with dilated ascending aorta and bicuspid aortic valve. Echocardiography. 2012; 30(2):121-6. DOI: 10.1111/echo.12004. View